GlassScriptPhysician profile
Jack S Bartoszek
NPI 1093714818
$7,403.08
in general payments reported to CMS, 2019-2025
23 companies · $634 in 2025
The $634 reported for 2025 was more than what 85% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $974 · 2021: $2,180 · 2022: $1,164 · 2023: $374 · 2024: $766 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,079.42 | 2022-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $1,052.02 | 2019-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $872.20 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $768.14 | 2020-2024 | Airsupra |
| Novo Nordisk INC | $432.88 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $393.74 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $324.89 | 2019-2020 | |
| Pfizer INC. | $276.89 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $247.88 | 2021 | |
| Abbvie INC. | $209.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $203.61 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.16 | 2019 | |
| Glaxosmithkline, LLC. | $178.45 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $159.72 | 2021 | |
| Allergan, INC. | $144.55 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Jazz Pharmaceuticals INC. | $124.99 | 2020 | |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.79 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Bartoszek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.